Supplementary data

Table S1. Primers

Primer	Sequence (5′ to 3′)	Target	Accession no.	Position	Reference
Tn-IR	ggggCgAATAgAgAAAACggAAAAAATCgTACgCTAAg	Tn*6001* inverted repeat	EF138817	1-38	6
bla$_{VIM1}$-F	TTATggAgCAgCAACgATgT	*bla*$_{VIM1}$	Y18050	3144-3163	4
bla$_{VIM1}$-R	CAAAAgTCCCgCTCCAACgA	*bla*$_{VIM1}$	Y18050	4063-4044	4
bla$_{VIM2}$-F	AAAgTTATgCCgCACTCACC	*bla*$_{VIM2}$	AF191564	1282-1301	4
bla$_{VIM2}$-R	TgCAACTTCATgTTATgCCg	*bla*$_{VIM2}$	AF191564	2146-2127	4
bla$_{IMP1-9}$-F	ATgAgCAAgTTATC/TT/AgTATTC	*bla*$_{IMP1-9}$	*bla*$_{IMP1-9}$	1-20	9
bla$_{IMP1-9}$-R	gCTgCAACgACTTgTTAg	*bla*$_{IMP}$59be	*bla*$_{IMP1-9}$	745-765	9
tnic-1B	TTTCCgAgCgAACAgTCgCT	integron determination	AY943084	4110-4091	5
tnpA-R3	AAAgACCTCggTAAgTTCgAgCCg	*tnpA*	EF138817	2210-2188	this study
tnpA-1805F	ACCTCCAACAaggCCggCgTATagCg	*tnpA*	EF138817	1805-1829	this study
Int-3686R	gTgCagTCggCTTCTgACgTTCagTgC	*int1*	EF138817	3711-3686	this study
Int-3692F	AACgTCAgAAgCCgACTgCACTATAgCAgCg	*int1*	EF138817	3692-3721	this study
VIM-5719R	AACTgTgCTTCCgggTAgTgTTgTTgAATCCg	*bla*$_{VIM3}$	EF138817	5749-5719	this study
VIM-outF	gAgCggATTCAACAACACTACCCg	*bla*$_{VIM3}$	EF138817	5716-5738	this study
aadB-outR	gCggCAgATTTCgCTCATCTgC	*aadB*	EF138817	7745-7725	this study
aadB-7666F	AAACgTTAggCCgCATggACACAACgC	*aadB*	EF138817	7666-7691	this study
sul110160R	TAggCATgATCTAACCCTCggTCTCTggC	*sul1*	EF138817	10187-10160	this study
10117F	AATCACCTTCTCggAAACCCTCgCg	*sul1*	EF138817	10117-10140	this study
12413R	gAACCgTCgATACAggCAATTACgTggg	*orfB*	EF138817	12439-12413	this study
12400F	gAAggAgAACAACAATgACCCACg	*orfB*	EF138817	12395-12417	this study

Table S2. Antimicrobial susceptibility of 308 CNSPA isolates at NTUH from 2000 to 2005

Antibiotic or resistance phenotype	No. (%) of isolates					
	2000 (*n*=60)	2001 (*n*=41)	2002 (*n*=21)	2003 (*n*=63)	2004 (*n*=70)	2005 (*n*=53)
Piperacillin/tazobactam	51 (85)	31 (76)	18 (86)	58 (92)	65 (93)	46 (87)
Ceftazidime	45 (75)	27 (66)	15 (71)	53 (84)	62 (89)	40 (75)
Cefepime	48 (80)	26 (63)	15 (71)	54 (86)	63 (90)	45 (85)
Aztreonam	43 (72)	25 (61)	11 (52)	54 (86)	63 (90)	42 (79)
Amikacin	15 (25)	10 (24)	8 (38)	35 (56)	38 (54)	21 (40)
Ciprofloxacin	33 (55)	17 (41)	16 (76)	49 (78)	65 (93)	42 (79)
Colistin-intermediate	26 (43)	14 (34)	6 (29)	13 (21)	15 (21)	26 (49)
COS[a]	0 (0)	0 (0)	0 (0)	12 (19)	9 (13)	6 (11)
COI[b]	0 (0)	0 (0)	0 (0)	1 (2)	2 (3)	0 (0)

[a]COS, colistin-only-susceptible, resistant to all antibiotics except colistin.

[b]COI, colistin-only-intermediate, resistant to all antibiotics except intermediate to colistin.

Table S3. Characteristics of VIM-3 production in 26 XDRPA isolates from six hospitals in Taiwan

XDRPA	VIM-3 [no. (%) of isolates]	In450 [no. (%) of isolates]		Tn*6001* [no. (%) of isolates]	
		COI[a]	COS[b]	COI[a]	COS[b]
N1[c] (*n*=11)	11 (100)	-	11 (100)[d]	-	7 (64)[d]
N2[c] (*n*=10)	4 (40)	-	4 (40)	-	4 (40)
C1[c] (*n*=1)	0 (0)	-	0 (0)	-	0 (0)
S1[c] (*n*=1)	0 (0)	-	0 (0)	-	0 (0)
S2[c] (*n*=2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
E[c] (*n*=1)	1 (100)	-	1 (100)	-	1 (100)
Total (*n*=26)	16 (62)	16 (62)		12 (46)	

[a]COI, colistin-only-intermediate, resistant to all antibiotics except intermediate to colistin.

[b]COS, colistin-only-susceptible, resistant to all antibiotics except colistin.

[c]Tri-service General Hospital, Taipei (North, N1); National Taiwan University Hospital, Taipei (North, N2); Taichung Veterans General Hospital (Central, C1); Chung-Ho Memorial Hospital; Kaohsiung Medical University, Kaohsiung (South, S1); Chi-Mei Medical Center,

Tainan (South, S2); and Buddhist Tzu-Chi General Hospital, Hualien (East, E).

[d]In450.2 (*n*=1) and Tn*6001.2* (*n*=1) were found in the same clinical isolate.

Figure S1. Hybridization of *bla*$_{VIM-3}$-specific probe to SpeI-digested chromosome fragments of *P. aeruginosa* isolates. (a) SpeI restriction patterns separated by PFGE. (b) Hybridization with a *bla*$_{VIM-3}$-specific probe. Lane M, lambda DNA ladder; lane 1, imipenem-susceptible *P. aeruginosa* from patient A; lane 2, imipenem-resistant *P. aeruginosa* from patient A; lane 3, no *bla*$_{VIM-3}$ imipenem-resistant *P. aeruginosa* control isolate; lane 4, NTUH-PA450 clinical isolate. The arrows indicate that acquisition of Tn*6001* caused band difference.